Zimberelimab
About Zimberelimab
Zimberelimab is the world's first fully human anti-PD-1 monoclonal antibody in market developed by the transgenic rat platform, OmniRat®.
The first indication of relapsed or refractory classical Hodgkin's lymphoma (r/r HL) was approved in China in August 2021. Zimberelimab has been selected into the "Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines for Malignant Lymphoma" for 4 consecutive years since 2020. Zimberelimab's second indication for recurrent or metastatic cervical cancer (r/m CC) was designated for Breakthrough Therapy and was approved in China in 2023.
In the pivotal clinical study of r/r HL, patients were observed with the Objective Response Rate (ORR) of 92.68%, the Disease Control Rate (DCR) of 96.43%, and 12-month Overall Survival (OS) rate of 99%.
About Hodgkin's lymphoma (HL)
HL is a rare malignant tumor that primarily affects the lymph nodes and the lymphatic system. HL is broadly classified into two main subtypes: nodular lymphocyte-predominant HL (NLPHL) and classic HL (cHL). Among these, cHL accounts for about 90% of all HL cases and is one of the most common cancers diagnosed in young adults.1
According to GLOBOCAN 2020, the estimated number of new HL cases worldwide was 83,087, with 6,829 cases reported in China. In China, the median age at diagnosis is around 30 years, and the age-standardized incidence rates (ASIR) is 0.57 per 100,000 population2.
1.中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会, 中国霍奇金淋巴瘤工作组. 中国霍奇金淋巴瘤的诊断与治疗指南（2022年版） [J] . 中华血液学杂志, 2022, 43(9) : 705-715. DOI: 10.3760/cma.j.issn.0253-2727.2022.09.001.
2. Liu W, Liu J, Song Y, Wang X, Mi L, Cai C, Zhao D, Wang L, Ma J, Zhu J. Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY). 2022 Apr 10;14(7):3175-3190. doi: 10.18632/aging.204006. Epub 2022 Apr 10. PMID: 35398840; PMCID: PMC9037266.